HOME >> MEDICINE >> NEWS
Supertron raises $3.5 million in Series C Financing

Supertron Technologies Inc. ( www.supertron.com), a leading developer of next-generation solutions for high-performance preclinical and clinical Magnetic Resonance Imaging (MRI) coils and probes announced today successfully financing $3.5 million with Amphion Innovations PLC. Supertron is based in the Enterprise Development Center (EDC) (www.njit-edc.org) at New Jersey Institute of Technology (NJIT) (www.njit.edu).

The financing round was supposed to close at $3 million, but the financing increased to $3.5 million due to overwhelming investor demand. "We are excited by the market response to our offering and the validation of the strategic direction for our product and technology set," said C. Richard Hullihen, Supertron CEO.

Supertron's products significantly improve the imaging capabilities of MRI scanners. The cryogenically cooled products enhance image resolution, reduce scan time and lower cost through faster image acquisition. These factors ultimately result in earlier disease detection, faster drug development, and integrated and/or guided therapeutics. Its solutions are applicable in both high and low-field clinical and preclinical research environments imaging objects from molecules to man.

Supertron is also targeting emerging MRI research applications in the fields of molecular imaging, x-nuclei applications, functional MRI, image-guided therapeutics, and orthopedics imaging.

Earlier financing for Supertron included a per-reviewed $2 million grant from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology (2003). The New Jersey Economic Development Authority (EDA) has also awarded the company $500,000 in springboard grants.

"We're indebted to our institutional ATP grant research partners at Brigham & Women's Hospital of Harvard Medical School and our ho
'"/>

Contact: Sheryl Weinstein
sheryl.m.weinstein@njit.edu
973-596-3436
New Jersey Institute of Technology
27-Jul-2006


Page: 1 2

Related medicine news :

1. Study raises new treatment possibilities for cognitive disorders
2. Having elevated risk factors in young adulthood raises risk of coronary calcium later on
3. Major discovery raises prospect of better patient care by improving platelet life span
4. Wartime raises stress, blood pressure rates in military offspring
5. Improved treatment raises medulloblastoma survival rate
6. Stopping medication too soon after receiving a drug-eluting stent raises risk of death
7. Selenium-protein deficiency raises prostate cancer risk
8. Childhood arthritis raises risk of broken bones
9. Rapid lung function decline raises risk of death and hospitalization
10. New research shows second-hand smoke raises diabetes risk
11. Obesity in middle age raises heart disease, diabetes risk in older age

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Supertron raises million Series Financing

(Date:6/19/2013)... The former internist for the St. Louis ... serves as director of prevention and wellness at St. ... personal encounter with a metabolic syndrome diagnosis and a ... , that he credits with sparking the paradigm-shift that ... practice. , “The average medical student gets 30 minutes ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on hand ... in a series of six workshops where people with and without ... the mosaic tiles in their permanent location under the direction of ... Maxwell. , This mural project began in March of 2013 ... three years ago with the goal of promoting ...
(Date:6/19/2013)... The US Food and Drug Administration (FDA) announced ... breast implant, Mentor Worldwide’s MemoryShape™. , The FDA approved Sientra/Silimed ... FDA announced the approval of the MemoryShape™ implant on June ... in women 22 years old or older and in ... FDA’s approval comes after six years of data from 955 ...
(Date:6/19/2013)... the mantra of neurologists treating stroke victims has been "time ... room quickly to receive a drug that dissolves the stroke-causing ... brain tissue is saved or lost. , But ... of giving the intravenous drug known as a tissue ... ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... fact that the incidence of cancer is many fold ... still have an inadequate understanding on how best to ... patients are occasionally included in clinical trials, those elderly ... elderly patients. Thus, the broader elderly patient population is ... in the Elderly Task Force is now starting a ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: